Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiaMedica TherapeuticsDMAC +2.97%31 Price-to-Tangible-Book is 9.49 as of Sep. 05, 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,131 Biotechnology companies, DiaMedica Therapeutics ranks worse than 81.26% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
DiaMedica Therapeutics Price-to-Tangible-Book Related Terms
DiaMedica Therapeutics Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for DiaMedica Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DMAC vs SABS, AGEN, PALI: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, DiaMedica Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DiaMedica Therapeutics Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where DiaMedica Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
DiaMedica Therapeutics (DMAC) has a Price-to-Tangible-Book of 9.49 as of Sep. 05, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on DiaMedica Therapeutics and its competitors. According to the industry distribution chart, DiaMedica Therapeutics ranks #919 out of 1131 companies in the Biotechnology industry, placing it in the top 81.3%.
Is DiaMedica Therapeutics' Price-to-Tangible-Book too high?
DiaMedica Therapeutics' current Price-to-Tangible-Book is 9.49. The Biotechnology industry median Price-to-Tangible-Book is 3.26. DiaMedica Therapeutics' value of 9.49 is 191.1% above this industry median. Based on the distribution chart, DiaMedica Therapeutics ranks #919 out of 1131 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Price-to-Tangible-Book compare to SABS and AGEN?
According to the Biotechnology industry distribution chart, DiaMedica Therapeutics ranks #919 out of 1131 companies for Price-to-Tangible-Book. This places DiaMedica Therapeutics in the lower half of its industry. The industry median Price-to-Tangible-Book is 3.26. DiaMedica Therapeutics' value of 9.49 is 191.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.26, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DiaMedica Therapeutics's current Price-to-Tangible-Book of 9.49 is 191.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on DiaMedica Therapeutics and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DiaMedica Therapeutics's current Price-to-Tangible-Book is 9.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Price-to-Tangible-Book of 9.49. The current Price-to-Tangible-Book is 9.49 and 191.1% above the Biotechnology industry median of 3.26. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Price-to-Tangible-Book is 9.49 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score
Get the complete analysis for DMAC
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMAC has been successfully added to your 
